Lorcaserin improves lipid profile, fatty liver scores in high-BMI adults

  • Tuccinardi D & al.
  • Diabetes Obes Metab
  • 6 Feb 2019

  • curated by Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lorcaserin (Belviq) leads to improved lipid profiles and Fatty Liver Index (FLI) scores in people with obesity, in addition to its effects on central adiposity.
  • Results suggest potential for cardiovascular disease (CVD) risk reduction with this drug.

Why this matters

  • Lorcaserin is a serotonin receptor agonist that promotes weight loss, in addition to its beneficial effects in type 2 diabetes. 
  • This study points to potential for benefits in CVD risk reduction and nonalcoholic fatty liver disease.

Key results

  • With lorcaserin vs placebo:
    • Fat mass (P<.001>, FLI (P<.0001>), and energy intake (P<.03>) all decreased.
    • Total cholesterol decreased (P<.04>
    • Total low-density lipoprotein (LDL) cholesterol decreased (P<.04> 
    • Small LDL decreased (P<.01>
    • High-density lipoprotein increased (P<.01> 

Study design

  • 6-month randomized, double-blinded placebo-controlled trial, 48 participants with obesity.
  • Lorcaserin group had greater BMI (P<.001 so adjustment for baseline bmi made.>
  • Funding: Drug from Arena Pharmaceuticals GmbH; Eisai, Inc.; Harvard Clinical and Translational Science Center; NIH.

Limitations

  • Small population, low retention rate, BMI difference between groups.